How long you take Kisqali depends on whether you’re being treated for early-stage or advanced breast cancer. For early breast cancer, the standard treatment length is 3 years. For advanced or metastatic breast cancer, there is no fixed endpoint: you continue taking it until the cancer progresses or side effects become too severe to manage.
The 28-Day Cycle
Regardless of your diagnosis, Kisqali follows a repeating 28-day cycle. You take the tablets once daily for 21 consecutive days, then stop for 7 days. That week off is built into every cycle and gives your body time to recover before starting again. Each cycle lasts exactly four weeks, and then you begin the next one.
The daily dose differs by stage. For early breast cancer, the dose is 400 mg (two tablets). For advanced or metastatic breast cancer, it’s 600 mg (three tablets). Both follow the same 21-days-on, 7-days-off pattern.
Early Breast Cancer: A 3-Year Course
If you’re taking Kisqali as an adjuvant treatment after surgery for stage II or III hormone receptor-positive, HER2-negative breast cancer, the FDA-approved treatment plan is 3 years. The goal is to reduce the risk of the cancer coming back, and the defined course gives both you and your care team a clear finish line. Treatment would stop sooner only if the cancer recurs or side effects become unmanageable.
This 3-year duration means roughly 39 cycles of the 28-day schedule. That’s a long commitment, and it’s normal for your oncologist to adjust your dose or temporarily pause treatment along the way if side effects flare up. A pause or dose reduction doesn’t necessarily mean you stop altogether.
Advanced or Metastatic Breast Cancer: No Set End Date
For advanced or metastatic breast cancer, Kisqali is taken continuously for as long as it’s working. In the clinical trials that led to its approval (the MONALEESA studies), patients stayed on treatment until their cancer progressed or toxicity forced them to stop. There was no predetermined number of months or cycles.
To give you a sense of real-world timelines, in the MONALEESA-3 trial, patients taking Kisqali with fulvestrant had a median progression-free survival of about 20.5 months, compared to roughly 12.8 months for those on fulvestrant alone. “Median” means half of patients stayed progression-free longer than that and half shorter. Some patients remain on the drug for years. Your individual timeline will depend on how well your cancer responds and how you tolerate the medication.
Reasons Treatment Might Stop Early
Your oncologist will monitor you with regular blood tests and heart rhythm checks throughout treatment. Several specific situations can lead to a permanent stop:
- Liver problems. Kisqali can elevate liver enzymes. If levels spike severely (more than 20 times the upper limit of normal) or if elevated enzymes occur alongside rising bilirubin, the drug is discontinued.
- Heart rhythm changes. Kisqali can prolong a specific interval in your heartbeat. If this measurement crosses a dangerous threshold on two separate occasions, or if it causes fainting or abnormal heart rhythms, the drug is stopped permanently.
- Lung inflammation. Severe or recurring lung inflammation (interstitial lung disease) requires permanent discontinuation.
- Severe skin reactions. Certain serious skin conditions, though rare, also mean stopping immediately.
Not every side effect means the end of treatment. Milder issues are often handled by lowering the dose or pausing for a cycle. For example, a first episode of moderately elevated liver enzymes typically leads to a temporary hold and dose reduction, not a permanent stop. Your oncologist will follow a structured plan for when to pause, reduce, or discontinue based on the severity of what comes up.
What to Expect Over Time
The first few months tend to involve the most frequent monitoring. You’ll likely have blood work checked before starting, at the beginning of the first several cycles, and then periodically after that. Heart rhythm monitoring follows a similar schedule, with checks becoming less frequent once your team is confident your body is tolerating the drug.
Many people adjust to the routine of the 21/7 cycle and find side effects are most noticeable in the first few months. Fatigue, nausea, and low white blood cell counts are among the more common issues. The week off each cycle provides some relief, and your body’s response often stabilizes as treatment continues. If you’re on the 3-year early breast cancer course, knowing the finish line can help with the mental side of staying on track. If you’re on open-ended treatment for advanced disease, regular scans will tell you and your oncologist whether the drug is still doing its job.